Anjali Pandey

USPTO Granted Patents = 81 (Patent Applications = 36)

CIPO Patents = 9 (Patent Applications = 12)

EPO Patents = 25 (Patent Applications = 27)

Average Co-Inventor Count = 4.4

ph-index = 11

Forward Citations = 387(Granted Patents)

Inventors with similar research interests:

Company Filing History:

35 out of 70

Portola Pharmaceuticals, Inc.

patents

24 out of 850

Millennium Pharmaceuticals Limited

Alexion Pharmaceuticals, Inc.

patents

5. 5 out of 730

Kyowa Hakko Kogyo Co., Ltd.

patents

6. 4 out of 4

Sudo Biosciences Limited

patents

7. 2 out of 363

Ortho-mcneil Pharmaceutical Corp.

patents

8. 2 out of 2

Ferro Therapeutics, Inc.

patents

9. 1 out of 36

Millenium Pharmaceuticals, Inc.

patents

10. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

81 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12350269 - Cerdulatinib for the treatment of b-cell malignancies (2025-07-08),

2. 12122785 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2024-10-22),

3. 12115154 - Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) (2024-10-15),

4. 12103937 - Substituted pyridines and pyridazines as TYK2 inhibitors (2024-10-01),

5. 12084458 - Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors (2024-09-10),

6. 11945782 - Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity (2024-04-02),

7. 11944619 - Phenylalanine small organic compounds to directly modulate PCSK9 protein activity (2024-04-02),

8. 11925637 - Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use (2024-03-12),

9. 11891369 - Compounds for binding proprotein convertase subtilisin/kexin type 9 (2024-02-06),

10. 11713309 - Solid forms of Cerdulatinib (2023-08-01),

11. 11613548 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors (2023-03-28),

12. 11414410 - Inhibitors of protein kinases (2022-08-16),

13. 11339145 - Synthesis of cerdulatinib (2022-05-24),

14. 11266645 - Methods for treating lymphoma (2022-03-08),

15. 11098040 - Compounds and methods of use (2021-08-24),

Title: The Innovative Journey of Anjali Pandey

Introduction: Anjali Pandey, a pioneering inventor based in Fremont, CA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents: Anjali Pandey's most recent patents include a cutting-edge artificial intelligence algorithm for predictive maintenance in manufacturing processes and a revolutionary wearable device for monitoring vital signs in real-time.

Career Highlights: With a background in computer science and engineering, Anjali Pandey has led several research projects at top tech companies, focusing on developing solutions that enhance efficiency and productivity in various industries.

Collaborations: Throughout her career, Anjali Pandey has collaborated with leading researchers and engineers from renowned universities and research institutions to push the boundaries of technological advancements and bring her inventions to life.

Conclusion: Anjali Pandey's relentless passion for innovation and her dedication to creating impactful solutions continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.